Baxter International Inc Stock News

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2022 financial results on Thursday, July 28,

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022. J

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 12.4% and a median increase of 10.3%. I've tracke

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will showcase its ongoing trajectory of transformation and growth at its 2022 Investor Conference, bein

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host an investor conference on Wednesday, May 25, 2022 in Glenview, Ill. Chairman and CEO Joe Alme

As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first

I've been on a crusade for the past 2 weeks to highlight investable dividend-paying quality business as we're experiencing a market drop. My work takes me now to revisit the company Baxter Internation

After years of a low interest rate environment, many investors have turned to equities, not only for the growth potential but also for solid and dependable dividends that help to provide an income str

Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.

Baxter International Inc. (NYSE:BAX ) Q1 2022 Results Conference Call April 28, 2022 8:30 AM ET Company Participants Clare Trachtman - VP, IR Joe Almeida - Chairman, CEO Giuseppe Accogli - COO Jay Sac

Baxter (BAX) delivered earnings and revenue surprises of 16.25% and 1.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.

Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.